EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Integrative Drug‐Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations

Anthony Aceto, Yue Wang, Da Yang iD

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Anthony Aceto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc, Gene Expression Regulation, Neoplastic, Transcriptome, Neoplasms. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MYC is among the most frequently dysregulated oncogenes in human cancer, yet its direct targeting remains a significant challenge. Here, we present an in‐silico integrative screening approach to identify compounds and combinations that can block MYC's oncogenic function by specifically disrupting its transcriptional regulatory function. Using a doxycycline (DOX)‐inducible model, we established a MYC loss‐of‐function (LOF) gene signature that specifically captures the molecular consequences corresponding to the loss of MYC's ability in transcriptional regulation. By integrating large‐scale post‐perturbation transcriptomic profiling from the CMAP database, we screened over 8300 drug‐induced profiles and identified 70 recurrent compounds that are predicted to antagonize MYC's transcriptional programs. To further enhance their therapeutic potential, we also developed an orthogonality analysis to pinpoint synergistic drug combinations that suppress MYC activity more effectively than single agents. Our scalable framework enables a rational and systematic identification of compounds with potential to antagonize MYC's oncogenic function by disrupting its transcriptional regulatory ability without necessarily decreasing its abundance. Our approach provides new insights on utilizing existing anticancer drugs to indirectly target MYC in MYC‐driven cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mycGene Expression Regulation, NeoplasticTranscriptomeNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansDrug SynergismGene Expression ProfilingDoxycyclineCell Line, Tumor

Stichwörter der Autor:innen

MYCdrug combinationsin‐silico screeningpost‐perturbation profiling

Substanzen

Proto-Oncogene Proteins c-mycMYC protein, humanDoxycyclineAntineoplastic Agents

Autor:innen und Institutionen

  • Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, USA.
  • UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA.
  • Department of Computational and System Biology, University of Pittsburgh, Pittsburgh, USA.

ORCID-Profile: Da Yang

Förderung

  • NIBIB NIH HHS
  • NCI NIH HHS

Zitieren

APA

Aceto, A., Wang, Y., & Yang, D. (2025). An Integrative Drug‐Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70044

Vancouver

Aceto A, Wang Y, Yang D. An Integrative Drug‐Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70044

BibTeX
@article{Aceto2025,
  author = {Aceto, Anthony and Wang, Yue and Yang, Da},
  title = {An Integrative Drug‐Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.70044}
}
Kostenlos starten →